GSA Capital Partners’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $163K | Sell |
17,430
-69,854
| -80% | -$653K | 0.01% | 1550 |
|
|
2025
Q1 | $1.07M | Buy |
87,284
+50,427
| +137% | +$619K | 0.1% | 314 |
|
|
2024
Q4 | $487K | Buy |
+36,857
| New | +$487K | 0.04% | 913 |
|
|
2024
Q1 | – | Sell |
-24,659
| Closed | -$533K | – | 1942 |
|
|
2023
Q4 | $533K | Buy |
+24,659
| New | +$533K | 0.04% | 753 |
|
|
2022
Q3 | – | Sell |
-11,542
| Closed | -$222K | – | 1832 |
|
|
2022
Q2 | $222K | Sell |
11,542
-31,758
| -73% | -$611K | 0.03% | 1025 |
|
|
2022
Q1 | $753K | Buy |
+43,300
| New | +$753K | 0.1% | 304 |
|
|
2021
Q1 | – | Sell |
-23,958
| Closed | -$533K | – | 1468 |
|
|
2020
Q4 | $533K | Sell |
23,958
-13,462
| -36% | -$299K | 0.09% | 390 |
|
|
2020
Q3 | $552K | Buy |
+37,420
| New | +$552K | 0.09% | 336 |
|
|
2020
Q1 | – | Sell |
-23,041
| Closed | -$202K | – | 1516 |
|
|
2019
Q4 | $202K | Buy |
+23,041
| New | +$202K | 0.02% | 1254 |
|
|
2019
Q3 | – | Sell |
-24,550
| Closed | -$229K | – | 1682 |
|
|
2019
Q2 | $229K | Buy |
24,550
+9,227
| +60% | +$86.1K | 0.03% | 1171 |
|
|
2019
Q1 | $80K | Buy |
+15,323
| New | +$80K | 0.01% | 1344 |
|
|
2018
Q3 | – | Sell |
-52,400
| Closed | -$368K | – | 1878 |
|
|
2018
Q2 | $368K | Buy |
+52,400
| New | +$368K | 0.02% | 1298 |
|